Hormone therapyFDA-approvedSecond-line
Abiraterone acetate
How it works
Blocks the production of androgens, which fuel prostate cancer growth.
Cancer types
Efficacy
Studies show that abiraterone acetate can slow disease progression and improve survival in patients with metastatic castration-resistant prostate cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Evaluating a New Medicine for Men with Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone, Apalutamide, and Prednisone in Treating Hormone-Naive Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| New Treatment Combination Shows Promise for Men with Advanced Prostate Cancer | Prostate Cancer | phase-3 | Median radiographic progression-free survival was 38.6 months in the niraparib + AAP group versus 8.3 months in the placebo + AAP group. | Source → |
| Low-Dose Abiraterone May Be a Feasible Alternative for Prostate Cancer Treatment | Prostate Cancer | phase-3 | Median PSA-PFS was 5.7 months with low-dose versus 3.8 months with standard-dose AA. | Source → |
| Abiraterone and Antiandrogen Therapy for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| New Delivery System for Prostate Cancer Treatment Shows Promise | Prostate Cancer | lab-study | The dissolution study demonstrated significantly higher ABT release from ABT-ssSNEDDS in comparison to free ABT after 2 h in pH 1.2 and 6.8 pH buffer. | Source → |
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | observational | Patients initiating enzalutamide had a 0.90-month longer overall survival compared to those initiating abiraterone acetate at 4 years. | Source → |
| Long-term effects of prostate cancer treatment studied | Prostate Cancer | phase-2 | A significant association between higher abiraterone acetate concentrations and better clinical benefit was observed (p = 0.041). | Source → |
| Radiation Therapy and Medication Combination Shows Promise for Prostate Cancer | Prostate Cancer | phase-2 | Biochemical response was detected in 79.6% of patients in the experimental arm, compared to 68.3% in the control arm. | Source → |
| Abiraterone Acetate May Be Better Than Docetaxel for Prostate Cancer | Prostate Cancer | observational | The abiraterone acetate group demonstrated significantly better progression-free survival (PFS) than the docetaxel group (not reached vs. 15.1 months: hazard ratio = 0.37; 95% confidence interval = 0.28-0.50; P < .001). | Source → |
| New Study Links Certain Prostate Cancer Drugs to Cardiovascular Risks | Prostate Cancer | observational | — | Source → |
| New Hormonal Agents May Help Some Prostate Cancer Patients | Prostate Cancer | phase-3 | AAP seems to be effective in improving OS among patients with VM (hazard ratio, HR: 0.58, 95% CI, 0.40-0.84, P = .004 for AAP). | Source → |
| Apalutamide May Help Prostate Cancer Patients Faster Than Abiraterone | Prostate Cancer | observational | Patients initiated on apalutamide were 53% more likely to achieve PSA90 than those initiated on abiraterone acetate within 6 months. | Source → |
| New Combination Therapy Shows Promise for Advanced Prostate Cancer | Prostate Cancer | phase-3 | Median radiographic progression-free survival was 16.6 months in the niraparib + AAP group compared with 10.9 months in the placebo + AAP group. | Source → |
| Combining Two Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-1 | Nine participants (33%) showed a 20% or greater decrease in prostate-specific antigen during study treatment. | Source → |
| Abiraterone and Docetaxel Compared in Prostate Cancer Treatment | Prostate Cancer | observational | The ABI group had a significantly better castration-resistant prostate cancer (CRPC)-free survival than the DOC group [hazard ratio (HR), 0.53; 95% confidence interval (CI), 0.34-0.82]. | Source → |
| Combining Two Compounds May Help Treat Prostate Cancer | Prostate Cancer | lab-study | The combination of abiraterone acetate and apigenin significantly inhibited LNCaP and PC3 cell survival in a manner more marked than observed with either single treatment. | Source → |
| Comparing Two Cancer Drugs for Advanced Prostate Cancer | Prostate Cancer | observational | — | Source → |
| Comparing Heart Risks of Two Prostate Cancer Treatments | Prostate Cancer | observational | — | Source → |
| Gene Changes in Blood May Predict Prostate Cancer Treatment Outcomes | Prostate Cancer | phase-2 | Plasma tumor DNA detection was associated with shorter overall survival (hazard ratio (HR): 2.89, 95% confidence intervals (CI): 1.77-4.73, P ≤ 0.0001) and progression-free survival (HR: 2.05; 95% CI: 1.36-3.11, P < 0.001). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.